Current trends in medical management of infantile hemangioma

Julie A. Ames, Jonathan M Sykes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of review Infantile hemangiomas are the most common benign, soft-tissue tumors of infancy, affecting between 5 and 10% of newborns, and up to 30% of premature infants. Morbidity may include disfigurement and scarring, difficulty in feeding, ulceration, vision loss, airway compromise, congestive heart failure, and death. Advances in understanding the pathogenesis of infantile hemangiomas have given rise to a number of promising treatments. This article reviews the current options for medical management of infantile hemangiomas. Recent findings In the proliferative phase of infantile hemangiomas, vascular endothelial growth factor and basic fibroblast growth factor have shown increased expression, and vascular endothelial growth factor expression has been up-regulated by adrenergic stimulation. Moreover, the role of the renin-angiotensin system in the pathogenesis of infantile hemangiomas has been demonstrated. Numerous medical options have been under investigation. Since 2008, propanolol has become the first-line therapy, whereas other medical treatments are used less frequently or when propanolol is unsuccessful. Summary Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas. Although emerging treatment options and modalities have shown promising results, there need to be high-quality multicenter randomized trials to support these preliminary data.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalCurrent Opinion in Otolaryngology and Head and Neck Surgery
Volume23
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Hemangioma
Propranolol
Vascular Endothelial Growth Factor A
Therapeutics
Fibroblast Growth Factor 2
Renin-Angiotensin System
Premature Infants
Adrenergic Agents
Multicenter Studies
Cicatrix
Heart Failure
Newborn Infant
Morbidity
Neoplasms

Keywords

  • Angiogenesis/vasculogenesis
  • Beta-blockers
  • Biology
  • Gene expression
  • Glucocorticosteroids
  • Infantile hemangioma
  • Medical management
  • Propranolol

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Current trends in medical management of infantile hemangioma. / Ames, Julie A.; Sykes, Jonathan M.

In: Current Opinion in Otolaryngology and Head and Neck Surgery, Vol. 23, No. 4, 01.07.2015, p. 286-291.

Research output: Contribution to journalArticle

@article{0c0a659b48f940eda917178fab045e2a,
title = "Current trends in medical management of infantile hemangioma",
abstract = "Purpose of review Infantile hemangiomas are the most common benign, soft-tissue tumors of infancy, affecting between 5 and 10{\%} of newborns, and up to 30{\%} of premature infants. Morbidity may include disfigurement and scarring, difficulty in feeding, ulceration, vision loss, airway compromise, congestive heart failure, and death. Advances in understanding the pathogenesis of infantile hemangiomas have given rise to a number of promising treatments. This article reviews the current options for medical management of infantile hemangiomas. Recent findings In the proliferative phase of infantile hemangiomas, vascular endothelial growth factor and basic fibroblast growth factor have shown increased expression, and vascular endothelial growth factor expression has been up-regulated by adrenergic stimulation. Moreover, the role of the renin-angiotensin system in the pathogenesis of infantile hemangiomas has been demonstrated. Numerous medical options have been under investigation. Since 2008, propanolol has become the first-line therapy, whereas other medical treatments are used less frequently or when propanolol is unsuccessful. Summary Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas. Although emerging treatment options and modalities have shown promising results, there need to be high-quality multicenter randomized trials to support these preliminary data.",
keywords = "Angiogenesis/vasculogenesis, Beta-blockers, Biology, Gene expression, Glucocorticosteroids, Infantile hemangioma, Medical management, Propranolol",
author = "Ames, {Julie A.} and Sykes, {Jonathan M}",
year = "2015",
month = "7",
day = "1",
doi = "10.1097/MOO.0000000000000170",
language = "English (US)",
volume = "23",
pages = "286--291",
journal = "Current Opinion in Otolaryngology and Head and Neck Surgery",
issn = "1068-9508",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Current trends in medical management of infantile hemangioma

AU - Ames, Julie A.

AU - Sykes, Jonathan M

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose of review Infantile hemangiomas are the most common benign, soft-tissue tumors of infancy, affecting between 5 and 10% of newborns, and up to 30% of premature infants. Morbidity may include disfigurement and scarring, difficulty in feeding, ulceration, vision loss, airway compromise, congestive heart failure, and death. Advances in understanding the pathogenesis of infantile hemangiomas have given rise to a number of promising treatments. This article reviews the current options for medical management of infantile hemangiomas. Recent findings In the proliferative phase of infantile hemangiomas, vascular endothelial growth factor and basic fibroblast growth factor have shown increased expression, and vascular endothelial growth factor expression has been up-regulated by adrenergic stimulation. Moreover, the role of the renin-angiotensin system in the pathogenesis of infantile hemangiomas has been demonstrated. Numerous medical options have been under investigation. Since 2008, propanolol has become the first-line therapy, whereas other medical treatments are used less frequently or when propanolol is unsuccessful. Summary Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas. Although emerging treatment options and modalities have shown promising results, there need to be high-quality multicenter randomized trials to support these preliminary data.

AB - Purpose of review Infantile hemangiomas are the most common benign, soft-tissue tumors of infancy, affecting between 5 and 10% of newborns, and up to 30% of premature infants. Morbidity may include disfigurement and scarring, difficulty in feeding, ulceration, vision loss, airway compromise, congestive heart failure, and death. Advances in understanding the pathogenesis of infantile hemangiomas have given rise to a number of promising treatments. This article reviews the current options for medical management of infantile hemangiomas. Recent findings In the proliferative phase of infantile hemangiomas, vascular endothelial growth factor and basic fibroblast growth factor have shown increased expression, and vascular endothelial growth factor expression has been up-regulated by adrenergic stimulation. Moreover, the role of the renin-angiotensin system in the pathogenesis of infantile hemangiomas has been demonstrated. Numerous medical options have been under investigation. Since 2008, propanolol has become the first-line therapy, whereas other medical treatments are used less frequently or when propanolol is unsuccessful. Summary Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas. Although emerging treatment options and modalities have shown promising results, there need to be high-quality multicenter randomized trials to support these preliminary data.

KW - Angiogenesis/vasculogenesis

KW - Beta-blockers

KW - Biology

KW - Gene expression

KW - Glucocorticosteroids

KW - Infantile hemangioma

KW - Medical management

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84942784084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942784084&partnerID=8YFLogxK

U2 - 10.1097/MOO.0000000000000170

DO - 10.1097/MOO.0000000000000170

M3 - Article

VL - 23

SP - 286

EP - 291

JO - Current Opinion in Otolaryngology and Head and Neck Surgery

JF - Current Opinion in Otolaryngology and Head and Neck Surgery

SN - 1068-9508

IS - 4

ER -